Nazmiye KAYA, İsmet Esra ZEYTİNCİ, MİNE ŞAHİNGÖZ

İnterferon alfa kullanan malign melanomlu bir hastada ortaya çıkan mani: Olgu sunumu

İnterferon alfa (IFN-α), immün sistem üzerindeki uyarıcı etkileri nedeniyle malign melanom, viral hepatitler ve multipl skleroz gibi bazı hastalıkların tedavisinde yaygın olarak kullanılmaktadır. IFN-α kullanımına bağlı olarak halsizlik, ateş, baş ağrısı ve kas ağrısı gibi grip benzeri belirtilerin yanı sıra, depresyon, anksiyete, psikoz, mani, intihar düşünceleri, somnolans ve deliryum gibi nöropsikiyatrik belirtiler de bildirilmektedir. Bu yazıda bipolar bozukluk için aile öyküsü bulunan, malign melanom nedeni ile IFN-α kullanımı sırasında mani gelişen bir olgu sunulmuştur.

Anahtar Kelimeler:

İlaç toksisitesi, Melanom, İnterferon-alfa, Erkek, Orta yaşlı, Duygudurum bozuklukları

Interferon alpha induced mania in a patient with malign melanoma: Case report

Interferon alpha is commonly used in the treatment of several diseases because of their stimulating effects on immune response, such as viral hepatitis, malign melanoma and multiple sclerosis. It was reported that IFN-α induce neuropsychiatric side effects such as depression, anxiety, psychosis, mania, suicidal ideation, somnolence and delirium in addition to flue like symptoms including weakness, fever, headache and myalgia. In this paper was presented a case of IFN-α induced mania in a patient treated for malign melanoma and with the family history of bipolar disorder.

Keywords:

Drug Toxicity, Melanoma, Interferon-alpha, Male, Middle Aged, Mood Disorders,

PDF

___

1. Irvin W, Legallo RL, Stoler MH, Rice LW, Taylor PT, Andersen WA. Vulvar melanoma: a retrospective analysis and literature review. Gynecol Oncol 2001; 83:457-465.
2. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistic 1998. CA Cancer J Clin 1998; 48:1-29.
3. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistic 1996. CA Cancer J Clin 1997; 47:5-27.
4. Robinson WA, Mughal TI, Thomas MR, Johnson M, Spiegel RJ. Treatment of metastatic malignant melanoma with recombinant interferon alpha 2. Immunobiology 1986; 172:275-282.
5. Regha S, Ring S, Bedikian A. Treatment of metastatic melanoma with combined cemotherapy containing cisplatin, vinblastine and dacarbazine (DTIC) and biothearapy using interleukin- 2 and interferon alpha. Ann Oncol 1996; 7:827-835.
6. Schiepers OJG, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29:201-217.
7. Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon- α: recognition and management. CNS Drugs 2005; 19:105-123.
8. Greenberg DB, Jonasch E, Gadd MA, Ryan BF, Everett JR, et al. Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes gabapentin may serve as a mood stabilizer. Cancer 2000; 89:356-362.
9. Uğuz Ş, Yurdagül E, Aydın H, Ünal M. Interferon kullanımına bağlı psikotik bozukluk: Olgu sunumu. Klinik Psikiyatri 2003; 6:170-173.
10. Valentine A, Meyers C, Kling MA, Richelson E, Hauser P. Mood and cognitive side effects of Interferon alpha therapy. Semin Oncol 1998; 25(Suppl.1):39-47.
11. Asnis GM, De La Garza R. Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. J Clin Gastroenterol 2006; 40:322-335.
12. Lindsay KL, Davis GL, Schiff ER, Bodenheimer HC, Balart CA, Dienstaq JL, et al. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group. Hepatology 1996; 24:1034-1040.
13. Cotler SJ, Wartelle CF, Larson AM, Gretch DR, Jensen DM, Carithers RL. Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C. J Viral Hepatitis 2000; 7: 211-217.
14. Feinstein A, O’Connor P, Feinstein K. Multiple sclerosis, interferon beta-1b and depression: a prospective investigation. J Neurol 2002; 249:815-820.
15. Patten SB, Metz LM. Interferon beta-1a and depression in relapsing–remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial. Mult Scler 2001; 7:243-248.
16. Scalori A, Apale P, Panizzuti F, Mascoli N, Pioltelli P, Pozzi M. Depression during interferon therapy for chronic viral hepatitis: early identification of patients at risk by means of a computerized test. Eur J Gastroenterol Hepatol 2000; 12:505-509.
17. Dell’Osso L, Pini S, Maggi L, Rucci P, Del Debbio A. Subthreshold mania as predictor of depression during interferon treatment in HCV+ patients without current or lifetime psychiatric disorders. J Psychosom Res 2007; 62:349-355.
18. Chiles C. Interferon alpha induced mood disorder with manic features. Gen Hosp Psychiatry 2001; 23:166-170.
19. Basanth KK, Jacob R, Jacob KS. Mania associated with interferon α2b treatment. J Postgrad Med 2006; 52:207-209.
20. Schafer M, Boetsch T, Laakmann S. Psychosis in a methadone-substituted patient during interferon alpha treatment of hepatitis C. Addiction 2000; 95:1101-1104.
21. Garcia-Pares G, Domenech C, Gil M. Psychosis induced by interferon-alpha. Psychosomatics 2002; 43:428-429.
22. Iancu I, Sverdlik A, Dannon PN, Lepkifker E. Bipolar disorder associated with interferon-alpha treatment. Postgrad Med J 1997; 73: 834-835.
23. Kingsley D. Interferon-alpha induced ‘tertiary mania.’ Hospital Med 1999; 60:381-382.
24. Asnisa GM, De La Garza R. Interferon-induced depression: Strategies in treatment. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29:808- 818.
25. Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon α. Neurology 1991; 41:672-676.
26. Rossi A, Renzetti D, D’albenzio L, Gianfelice D, Kalyvoka A, Rınaldı O. Case of mania induced by withdrawal of interferon alpha in a patient affected with bipolar disorder. Psychiatry Clin Neurosci 2002; 56:647-648.
27. Carpiniello B, Orru MG, Baita A. Pariante M. Mania induced by withdrawal of treatment with interferon alfa. Arch Gen Psychiatry 1998; 55:88-89.
28. Loftis JM, Hauser P. The phenomenology and treatment of interferon-induced depression. J Affect Disord 2004; 82:175-190.
29. Trask PC, Paterson AG, Esper G, Pau J, Redman B: Longutidunal course of depression fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon. Psycho-Oncology 2004; 13:526-536.
30. Dobmeier M, Frick E, Frank S, Franke C, Wolfersdorf M. Schizophrenic psychosis: a contraindication for treatment of hepatitis C with interferon alpha? Pharmacopsychiatry 2000; 33:72-74.
31. Rifai MA, Moles JK, Short DD. Hepatitis C treatment eligibility and outcomes among patients with psychiatric illness. Psychiatr Serv 2006;57:570-574.
32. Richards JM, Mehta N, Ramming K, Skosey P. Squential chemo immuno therapy in the treatment of metastatic melanoma. J Clin Oncol 1992; 10:1338-1343.
33. Yokoyama A, Kimura Y, Shigemura J. Psychiatric side effects of interferon. J Toxicol Sci 1996; 21:93-96.
34. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25:283-291.
35. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1996; 26 (Suppl.1):112-121.
36. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alpha interferon. J Hepatol 1996; 124:38-47.
37. Onyike CU, Bonner JO, Lyketsos CG, Treisman GJ. Mania during treatment of chronic hepatitis C with pegylated ınterferon and ribavirin. Am J Psychiatry 2004; 161:429-435.
38. Rapaport MH, Guylai L, Whybrow P. Immune parameters in rapid cycling bipolar patients before and after lithium treatment. J Psychiatry Res 1999;33:335-340.
39. Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: reanalysis of he ECA database taking into account subthreshold cases. J Affect Disord 2003;73:123-131.